| Year |
Citation |
Score |
| 2023 |
Maziarz RT, Devine S, Garrison LP, Agodoa I, Badaracco J, Gitlin M, Perales MA. Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient. Transplantation and Cellular Therapy. PMID 37364775 DOI: 10.1016/j.jtct.2023.06.013 |
0.312 |
|
| 2023 |
Babigumira JB, Karichu JK, Clark S, Cheng MM, Garrison LP, Maniecki MB, Hamid SS. Assessing the potential cost-effectiveness of centralised versus point-of-care testing for hepatitis C virus in Pakistan: a model-based comparison. Bmj Open. 13: e066770. PMID 37142306 DOI: 10.1136/bmjopen-2022-066770 |
0.574 |
|
| 2022 |
Postma MJ, Noone D, Rozenbaum MH, Carter JA, Botteman MF, Fenwick E, Garrison LP. Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose? Orphanet Journal of Rare Diseases. 17: 157. PMID 35382853 DOI: 10.1186/s13023-022-02283-z |
0.313 |
|
| 2021 |
Thornburg CD, Adamski K, Cook K, Vembusubramanian M, Sendhil SR, Hinds D, Chen E, Sammon J, Solari P, Garrison LP, Croteau SE. Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States. Journal of Managed Care & Specialty Pharmacy. 1-12. PMID 34958235 DOI: 10.18553/jmcp.2021.21368 |
0.326 |
|
| 2021 |
Dabbous M, Toumi M, Simoens S, Wasem J, Saal G, Wang Y, Osuna JLH, François C, Annemans L, Graf von der Schulenburg JM, Sola-Morales O, Malone D, Garrison LP. Amortization of gene replacement therapies: A health policy analysis exploring a mechanism for mitigating budget impact of high-cost treatments. Health Policy (Amsterdam, Netherlands). PMID 34863529 DOI: 10.1016/j.healthpol.2021.11.005 |
0.313 |
|
| 2021 |
Garrison LP, Jiao B, Dabbous O. Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapies. Journal of Managed Care & Specialty Pharmacy. 27: 674-681. PMID 33908277 DOI: 10.18553/jmcp.2021.27.5.674 |
0.304 |
|
| 2021 |
Zamora B, Garrison LP, Unuigbe A, Towse A. Reconciling ACEA and MCDA: is there a way forward for measuring cost-effectiveness in the U.S. healthcare setting? Cost Effectiveness and Resource Allocation : C/E. 19: 13. PMID 33648523 DOI: 10.1186/s12962-021-00266-8 |
0.356 |
|
| 2020 |
Coyle D, Durand-Zaleski I, Farrington J, Garrison L, Graf von der Schulenburg JM, Greiner W, Longworth L, Meunier A, Moutié AS, Palmer S, Pemberton-Whiteley Z, Ratcliffe M, Shen J, Sproule D, Zhao K, et al. HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. The European Journal of Health Economics : Hepac : Health Economics in Prevention and Care. PMID 32794011 DOI: 10.1007/S10198-020-01212-W |
0.33 |
|
| 2020 |
Quinn C, Garrison LP, Pownell AK, Atkins MB, de Pouvourville G, Harrington K, Ascierto PA, McEwan P, Wagner S, Borrill J, Wu E. Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. Journal For Immunotherapy of Cancer. 8. PMID 32661115 DOI: 10.1136/Jitc-2020-000648 |
0.31 |
|
| 2020 |
Duarte HA, Babigumira JB, Enns EA, Stauffer DC, Shafer RW, Beck IA, Garrison LP, Chung MH, Frenkel LM, Bendavid E. Cost-effectiveness analysis of pre-ART HIV drug resistance testing in Kenyan women. Eclinicalmedicine. 22: 100355. PMID 32490370 DOI: 10.1016/J.Eclinm.2020.100355 |
0.634 |
|
| 2020 |
Garrison LP, Zamora B, Li M, Towse A. Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment-Rationale and Empirical Support. Journal of Managed Care & Specialty Pharmacy. 26: 400-406. PMID 32223599 DOI: 10.18553/Jmcp.2020.26.4.400 |
0.375 |
|
| 2020 |
Cook K, Forbes SP, Adamski K, Ma JJ, Chawla A, Garrison LP. Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A. Journal of Medical Economics. 1. PMID 31971453 DOI: 10.1080/13696998.2020.1721508 |
0.424 |
|
| 2020 |
Khaki AR, Diamantopoulos LN, Zimmerman M, Garrison LP, Grivas P. Assessing the potential cost-effectiveness of the addition of atezolizumab to first-line platinum chemotherapy in advanced urothelial cancer: Implications for value-based pricing. Journal of Clinical Oncology. 38: 5031-5031. DOI: 10.1200/jco.2020.38.15_suppl.5031 |
0.363 |
|
| 2019 |
Garrison LP, Neumann PJ, Willke RJ. Reflections on the ISPOR Special Task Force on U.S. Value Frameworks: Implications of a Health Economics Approach for Managed Care Pharmacy. Journal of Managed Care & Specialty Pharmacy. 25: 1185-1192. PMID 31663458 DOI: 10.18553/Jmcp.2019.25.11.1185 |
0.302 |
|
| 2019 |
Yu PP, Eton O, Garrison LP. Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer. Journal For Immunotherapy of Cancer. 7: 235. PMID 31481112 DOI: 10.1186/S40425-019-0707-9 |
0.379 |
|
| 2019 |
Adamson B, Garrison L, Barnabas RV, Carlson JJ, Kublin J, Dimitrov D. Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA. Journal of the International Aids Society. 22: e25373. PMID 31402591 DOI: 10.1002/Jia2.25373 |
0.3 |
|
| 2019 |
Dankó D, Blay JY, Garrison LP. Challenges in the value assessment, pricing and funding of targeted combination therapies in oncology. Health Policy (Amsterdam, Netherlands). PMID 31337514 DOI: 10.1016/J.Healthpol.2019.07.009 |
0.312 |
|
| 2019 |
Wurcel V, Cicchetti A, Garrison L, Kip MMA, Koffijberg H, Kolbe A, Leeflang MMG, Merlin T, Mestre-Ferrandiz J, Oortwijn W, Oosterwijk C, Tunis S, Zamora B. The Value of Diagnostic Information in Personalised Healthcare: A Comprehensive Concept to Facilitate Bringing This Technology into Healthcare Systems. Public Health Genomics. 22: 8-15. PMID 31330522 DOI: 10.1159/000501832 |
0.336 |
|
| 2019 |
Li M, Basu A, Bennette C, Veenstra D, Garrison LP. How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 22: 777-784. PMID 31277824 DOI: 10.1016/J.Jval.2019.02.002 |
0.411 |
|
| 2019 |
Garrison LP, Jansen JP, Devlin NJ, Griffin S. Novel Approaches to Value Assessment Within the Cost-Effectiveness Framework. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 22: S12-S17. PMID 31200801 DOI: 10.1016/J.Jval.2019.04.1915 |
0.405 |
|
| 2019 |
Yeung K, Suh K, Garrison LP, Carlson JJ. Defining and Managing High-Priced Cures: Healthcare Payers' Opinions. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 22: 648-655. PMID 31198181 DOI: 10.1016/J.Jval.2018.11.012 |
0.417 |
|
| 2019 |
Vodicka EL, Chung MH, Zimmermann MR, Kosgei RJ, Lee F, Mugo NR, Okech TC, Sakr SR, Stergachis A, Garrison LP, Babigumira JB. Estimating the costs of HIV clinic integrated versus non-integrated treatment of pre-cancerous cervical lesions and costs of cervical cancer treatment in Kenya. Plos One. 14: e0217331. PMID 31170193 DOI: 10.1371/Journal.Pone.0217331 |
0.646 |
|
| 2019 |
Guzauskas GF, Pollom EL, Stieber VW, Wang BCM, Garrison L. Tumor treating fields and maintenance temozolomide for newly diagnosed glioblastoma: a cost-effectiveness study. Journal of Medical Economics. 1. PMID 31050315 DOI: 10.1080/13696998.2019.1614933 |
0.343 |
|
| 2019 |
Garrison LP, Babigumira J, Tournier C, Goertz HP, Lubinga SJ, Perez EA. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 22: 408-415. PMID 30975391 DOI: 10.1016/J.Jval.2018.11.014 |
0.628 |
|
| 2019 |
Garrison LP, Jackson T, Paul D, Kenston M. Value-Based Pricing for Emerging Gene Therapies: The Economic Case for a Higher Cost-Effectiveness Threshold. Journal of Managed Care & Specialty Pharmacy. 1-7. PMID 30784347 DOI: 10.18553/Jmcp.2019.18378 |
0.351 |
|
| 2019 |
Adamson B, El-Sadr W, Dimitrov D, Gamble T, Beauchamp G, Carlson JJ, Garrison L, Donnell D. The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 22: 194-202. PMID 30711064 DOI: 10.1016/J.Jval.2018.09.001 |
0.382 |
|
| 2018 |
Mejía A, Gilardino R, Kristensen FB, Garrison LP. Value-Based Pricing in Latin America: How Far Away Are We? Value in Health Regional Issues. 17: 219-223. PMID 30528780 DOI: 10.1016/J.Vhri.2018.09.007 |
0.378 |
|
| 2018 |
Mauskopf J, Standaert B, Connolly MP, Culyer AJ, Garrison LP, Hutubessy R, Jit M, Pitman R, Revill P, Severens JL. Economic Analysis of Vaccination Programs. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 21: 1133-1149. PMID 30314613 DOI: 10.1016/J.Jval.2018.08.005 |
0.364 |
|
| 2018 |
Garrison LP, Neumann PJ, Willke RJ, Basu A, Danzon PM, Doshi JA, Drummond MF, Lakdawalla DN, Pauly MV, Phelps CE, Ramsey SD, Towse A, Weinstein MC. A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7]. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 21: 161-165. PMID 29477394 DOI: 10.1016/J.Jval.2017.12.009 |
0.428 |
|
| 2018 |
Willke RJ, Neumann PJ, Garrison LP, Ramsey SD. Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6]. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 21: 155-160. PMID 29477393 DOI: 10.1016/J.Jval.2017.12.011 |
0.403 |
|
| 2018 |
Lakdawalla DN, Doshi JA, Garrison LP, Phelps CE, Basu A, Danzon PM. Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3]. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 21: 131-139. PMID 29477390 DOI: 10.1016/J.Jval.2017.12.007 |
0.383 |
|
| 2018 |
Garrison LP, Pauly MV, Willke RJ, Neumann PJ. An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2]. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 21: 124-130. PMID 29477389 DOI: 10.1016/J.Jval.2017.12.006 |
0.362 |
|
| 2018 |
Neumann PJ, Willke RJ, Garrison LP. A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1]. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 21: 119-123. PMID 29477388 DOI: 10.1016/J.Jval.2017.12.012 |
0.336 |
|
| 2018 |
Lubinga S, Babigumira J, Graham S, Mukose A, Garrison L, Basu A. Heterogeneity in Preferences for Medical Male Circumcision Services: A Discrete Choice Experiment Among Uncircumcised Men In Fishing Communities in Uganda Value in Health. 21: S127. DOI: 10.1016/J.Jval.2018.04.961 |
0.513 |
|
| 2017 |
Yenikomshian MA, White AG, Carson ME, Garrison LP, Oderda GM, Biskupiak JE, Hlavacek PR, Roland CL. Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients. Journal of Opioid Management. 13: 291-301. PMID 29199395 DOI: 10.5055/Jom.2017.0398 |
0.336 |
|
| 2017 |
Li M, Nyabigambo A, Navvuga P, Nuwamanya E, Nuwasiima A, Kaganda P, Asiimwe FT, Vodicka E, Mugisha NM, Mukose A, Kwesiga DK, Lubinga SJ, Garrison LP, Babigumira JB. Acceptability of cervical cancer screening using visual inspection among women attending a childhood immunization clinic in Uganda. Papillomavirus Research (Amsterdam, Netherlands). 4: 17-21. PMID 29179864 DOI: 10.1016/J.Pvr.2017.06.004 |
0.576 |
|
| 2017 |
Yeung K, Suh K, Basu A, Garrison LP, Bansal A, Carlson JJ. Paying for Cures: How Can We Afford It? Managed Care Pharmacy Stakeholder Perceptions of Policy Options to Address Affordability of Prescription Drugs. Journal of Managed Care & Specialty Pharmacy. 23: 1084-1090. PMID 28944726 DOI: 10.18553/Jmcp.2017.23.10.1084 |
0.373 |
|
| 2017 |
Babigumira JB, Sharara FI, Garrison LP. Projecting the potential impact of the Cap-Score™ on clinical pregnancy, live births, and medical costs in couples with unexplained infertility. Journal of Assisted Reproduction and Genetics. PMID 28942518 DOI: 10.1007/S10815-017-1021-4 |
0.654 |
|
| 2017 |
Garrison LP, Towse A. Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics. Journal of Personalized Medicine. 7. PMID 28869571 DOI: 10.3390/Jpm7030010 |
0.353 |
|
| 2017 |
Banerjee S, Garrison LP, Danel A, Ochoa Gautier JB, Flum DR. Effects of arginine-based immunonutrition on inpatient total costs and hospitalization outcomes for patients undergoing colorectal surgery. Nutrition (Burbank, Los Angeles County, Calif.). PMID 28734748 DOI: 10.1016/J.Nut.2017.06.002 |
0.359 |
|
| 2017 |
Zimmermann MR, Vodicka E, Babigumira JB, Okech T, Mugo N, Sakr S, Garrison LP, Chung MH. Cost-effectiveness of cervical cancer screening and preventative cryotherapy at an HIV treatment clinic in Kenya. Cost Effectiveness and Resource Allocation : C/E. 15: 13. PMID 28725164 DOI: 10.1186/S12962-017-0075-6 |
0.643 |
|
| 2017 |
Banerjee S, Garrison LP, Flum DR, Arterburn DE. Cost and Health Care Utilization Implications of Bariatric Surgery Versus Intensive Lifestyle and Medical Intervention for Type 2 Diabetes. Obesity (Silver Spring, Md.). PMID 28722299 DOI: 10.1002/Oby.21927 |
0.333 |
|
| 2017 |
Adamson BJS, Carlson JJ, Kublin JG, Garrison LP. The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United States. Vaccines. 5. PMID 28538691 DOI: 10.3390/Vaccines5020013 |
0.357 |
|
| 2017 |
Garrison LP, Kamal-Bahl S, Towse A. Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 20: 213-216. PMID 28237197 DOI: 10.1016/J.Jval.2016.12.005 |
0.428 |
|
| 2017 |
Vodicka EL, Babigumira JB, Mann MR, Kosgei RJ, Lee F, Mugo NR, Okech TC, Sakr SR, Garrison LP, Chung MH. Costs of integrating cervical cancer screening at an HIV clinic in Kenya. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics. 136: 220-228. PMID 28099724 DOI: 10.1002/Ijgo.12025 |
0.637 |
|
| 2017 |
Babigumira JB, Li M, Boudreau DM, Best JH, Garrison LP. Estimating the Cost of Illness of Giant Cell Arteritis in the United States. Rheumatology and Therapy. PMID 28084585 DOI: 10.1007/s40744-017-0052-8 |
0.637 |
|
| 2017 |
Kaufman HL, Atkins MB, Dicker AP, Jim HS, Garrison LP, Herbst RS, McGivney WT, Silverstein S, Wigginton JM, Yu PP. The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting Journal For Immunotherapy of Cancer. 5. DOI: 10.1186/S40425-017-0241-6 |
0.329 |
|
| 2017 |
Towse A, Garrison L. Value assessment in precision cancer medicine Journal of Cancer Policy. 11: 48-53. DOI: 10.1016/J.Jcpo.2016.09.003 |
0.349 |
|
| 2016 |
Garrison LP, Zimmermann MR, Young CH, Crittendon J, Généreux P. Cost-effectiveness analysis of the orbital atherectomy system: Two-year follow-up. Cardiovascular Revascularization Medicine : Including Molecular Interventions. PMID 28017543 DOI: 10.1016/J.Carrev.2016.12.005 |
0.304 |
|
| 2016 |
Chen Y, Guzauskas GF, Gu C, Wang BC, Furnback WE, Xie G, Dong P, Garrison LP. Precision Health Economics and Outcomes Research to Support Precision Medicine: Big Data Meets Patient Heterogeneity on the Road to Value. Journal of Personalized Medicine. 6. PMID 27827859 DOI: 10.3390/Jpm6040020 |
0.411 |
|
| 2016 |
Garrison LP. Cost-Effectiveness and Clinical Practice Guidelines: Have We Reached a Tipping Point?-An Overview. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 19: 512-5. PMID 27565265 DOI: 10.1016/J.Jval.2016.04.018 |
0.407 |
|
| 2016 |
Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, Babigumira JB, Garrison LP, Stergachis A. Active Surveillance versus Spontaneous Reporting for First-Line Antiretroviral Medicines in Namibia: A Cost-Utility Analysis. Drug Safety. PMID 27314405 DOI: 10.1007/S40264-016-0432-Y |
0.657 |
|
| 2016 |
Malone DC, Berg NS, Claxton K, Garrison LP, IJzerman M, Marsh K, Neumann PJ, Sculpher M, Towse A, Uyl-de Groot C, Weinstein MC. International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27298420 DOI: 10.1200/Jco.2015.64.4328 |
0.382 |
|
| 2016 |
Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, Baeten JM, Babigumira JB, Garrison LP, Stergachis A. Sentinel site active surveillance of safety of first-line antiretroviral medicines in Namibia. Pharmacoepidemiology and Drug Safety. PMID 27134056 DOI: 10.1002/Pds.4022 |
0.592 |
|
| 2016 |
Babigumira JB, Jenny AM, Bartlein R, Stergachis A, Garrison LP. Health technology assessment in low- and middle-income countries: A landscape assessment Journal of Pharmaceutical Health Services Research. DOI: 10.1111/Jphs.12120 |
0.609 |
|
| 2016 |
Babigumira J, Sharara F, Garrison L. Potential impact of the Cap-Score test™ on clinical pregnancy and medical costs in couples with unexplained infertility Fertility and Sterility. 106: e299. DOI: 10.1016/J.Fertnstert.2016.07.848 |
0.636 |
|
| 2015 |
Chambers J, Généreux P, Lee A, Lewin J, Young C, Crittendon J, Mann M, Garrison LP. The potential cost-effectiveness of the Diamondback 360® Coronary Orbital Atherectomy System for treating de novo, severely calcified coronary lesions: an economic modeling approach. Therapeutic Advances in Cardiovascular Disease. PMID 26702147 DOI: 10.1177/1753944715622145 |
0.31 |
|
| 2015 |
Garrison LP, Lewin J, Young CH, Généreux P, Crittendon J, Mann MR, Brindis RG. The clinical and cost burden of coronary calcification in a Medicare cohort: An economic model to address under-reporting and misclassification. Cardiovascular Revascularization Medicine : Including Molecular Interventions. PMID 26361178 DOI: 10.1016/J.Carrev.2015.08.002 |
0.307 |
|
| 2015 |
Canestaro WJ, Pritchard DE, Garrison LP, Dubois R, Veenstra DL. Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion test Assessment Tool (CAT). Journal of Managed Care & Specialty Pharmacy. 21: 700-12. PMID 26233542 DOI: 10.18553/Jmcp.2015.21.8.700 |
0.314 |
|
| 2015 |
Garrison LP, Babigumira JB, Masaquel A, Wang BC, Lalla D, Brammer M. The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Breast Cancer. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 18: 541-6. PMID 26091608 DOI: 10.1016/J.Jval.2015.01.012 |
0.613 |
|
| 2015 |
Wang B, Roth JA, Nguyen H, Felber E, Furnback W, Garrison LP. The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States. Plos One. 10: e0121915. PMID 25849542 DOI: 10.1371/Journal.Pone.0121915 |
0.344 |
|
| 2015 |
Sullivan SD, Yeung K, Vogeler C, Ramsey SD, Wong E, Murphy CO, Danielson D, Veenstra DL, Garrison LP, Burke W, Watkins JB. Design, implementation, and first-year outcomes of a value-based drug formulary. Journal of Managed Care & Specialty Pharmacy. 21: 269-75. PMID 25803760 DOI: 10.18553/Jmcp.2015.21.4.269 |
0.348 |
|
| 2015 |
Perrin A, Sherman S, Pal S, Chua A, Gorritz M, Liu Z, Wang X, Culver K, Casciano R, Garrison LP. Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US. Journal of Medical Economics. 18: 200-9. PMID 25422989 DOI: 10.3111/13696998.2014.985789 |
0.319 |
|
| 2015 |
Babigumira J, Li M, Boudreau D, Best J, Garrison L. THU0347 Estimating the Cost of Illness of Giant Cell Arteritis Annals of the Rheumatic Diseases. 74: 321.1-321. DOI: 10.1136/Annrheumdis-2015-Eular.5013 |
0.648 |
|
| 2015 |
Babigumira J, Li M, Boudreau D, Best J, Garrison L. Estimating The Cost Of Illness Of Giant Cell Arteritis Value in Health. 18: A138. DOI: 10.1016/J.Jval.2015.03.805 |
0.614 |
|
| 2015 |
Garrison LP, Lewin J, Young CH, Généreux P, Crittendon J, Mann MR, Brindis RG. CRT-171 The Clinical and Cost Burden of Coronary Calcification: An Economic Model to Address Under-reporting and Misclassification Jacc: Cardiovascular Interventions. 8: S30. DOI: 10.1016/J.Jcin.2014.12.224 |
0.352 |
|
| 2014 |
Agapova M, Devine EB, Bresnahan BW, Higashi MK, Garrison LP. Applying quantitative benefit-risk analysis to aid regulatory decision making in diagnostic imaging: methods, challenges, and opportunities. Academic Radiology. 21: 1138-43. PMID 25107866 DOI: 10.1016/J.Acra.2014.05.006 |
0.333 |
|
| 2014 |
Akhavan A, Shnorhavorian M, Garrison LP, Merguerian PA. Resource utilization and costs associated with the diagnostic evaluation of nonrefluxing primary hydronephrosis in infants. The Journal of Urology. 192: 919-24. PMID 24704116 DOI: 10.1016/J.Juro.2014.03.110 |
0.382 |
|
| 2014 |
Babigumira JB, Stergachis A, Choi HL, Dodoo A, Nwokike J, Garrison LP. A framework for assessing the economic value of pharmacovigilance in low- and middle-income countries. Drug Safety. 37: 127-34. PMID 24550105 DOI: 10.1007/S40264-014-0143-1 |
0.672 |
|
| 2014 |
Wang BC, Wong ES, Alfonso-Cristancho R, He H, Flum DR, Arterburn DE, Garrison LP, Sullivan SD. Cost-effectiveness of bariatric surgical procedures for the treatment of severe obesity. The European Journal of Health Economics : Hepac : Health Economics in Prevention and Care. 15: 253-63. PMID 23526126 DOI: 10.1007/S10198-013-0472-5 |
0.312 |
|
| 2014 |
Babigumira JB, Santos E, Antao VP, Wang B, Portera CC, Kamath T, Garrison LP. Projecting the cost-effectiveness of pertuzumab with trastuzumab and docetaxel in the neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early breast cancer. Journal of Clinical Oncology. 32: 642-642. DOI: 10.1200/Jco.2014.32.15_Suppl.642 |
0.63 |
|
| 2014 |
Mann M, Babigumira J, Garrison L, Chung M. Assessing the Potential Cost-Effectiveness of Alternative Methods to Screen for Cervical Cancer Among HIV-Positive Women in Kenya Value in Health. 17: A82. DOI: 10.1016/J.Jval.2014.03.481 |
0.602 |
|
| 2013 |
Towse A, Ossa D, Veenstra D, Carlson J, Garrison L. Understanding the economic value of molecular diagnostic tests: case studies and lessons learned. Journal of Personalized Medicine. 3: 288-305. PMID 25562729 DOI: 10.3390/Jpm3040288 |
0.388 |
|
| 2013 |
Towse A, Garrison LP. Economic incentives for evidence generation: promoting an efficient path to personalized medicine. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 16: S39-43. PMID 24034311 DOI: 10.1016/J.Jval.2013.06.003 |
0.378 |
|
| 2013 |
Garrison LP, Towse A, Briggs A, de Pouvourville G, Grueger J, Mohr PE, Severens JL, Siviero P, Sleeper M. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 16: 703-19. PMID 23947963 DOI: 10.1016/J.Jval.2013.04.011 |
0.42 |
|
| 2013 |
Garrison LP, Lalla D, Brammer M, Babigumira JB, Wang B, Perez EA. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status. Cancer. 119: 3113-22. PMID 23775560 DOI: 10.1002/cncr.28196 |
0.632 |
|
| 2013 |
Campbell JD, Zerzan J, Garrison LP, Libby AM. Comparative-effectiveness research to aid population decision making by relating clinical outcomes and quality-adjusted life years. Clinical Therapeutics. 35: 364-70. PMID 23477685 DOI: 10.1016/J.Clinthera.2013.02.011 |
0.304 |
|
| 2013 |
Garrison LP, Wang ST, Huang H, Ba-Mancini A, Shi H, Chen K, Korves C, Dhawan R, Cakana A, van de Velde H, Corzo D, Duh MS. The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment. The Oncologist. 18: 27-36. PMID 23299777 DOI: 10.1634/Theoncologist.2011-0380 |
0.424 |
|
| 2013 |
Barzey V, Atkins MB, Garrison LP, Asukai Y, Kotapati S, Penrod JR. Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis. Journal of Medical Economics. 16: 202-12. PMID 23057750 DOI: 10.3111/13696998.2012.739226 |
0.413 |
|
| 2013 |
Garau M, Towse A, Garrison L, Housman L, Ossa D. Can and should value-based pricing be applied to molecular diagnostics? Personalized Medicine. 10: 61-72. DOI: 10.2217/Pme.12.99 |
0.372 |
|
| 2013 |
Wang BCM, Furnback WE, Ney JP, Garrison LP, Fang C. THU0511 Estimating the Burden of Illness of Fibromyalgia in Taiwan Annals of the Rheumatic Diseases. 72. DOI: 10.1136/Annrheumdis-2013-Eular.1039 |
0.444 |
|
| 2012 |
Casciano R, Chulikavit M, Perrin A, Liu Z, Wang X, Babigumira J, Garrison LP. Cost-effectiveness of treating patients with advanced progressive pancreatic neuroendocrine tumor with everolimus versus sunitinib in the United States. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 226. PMID 27983058 DOI: 10.1200/Jco.2012.30.15_Suppl.E14525 |
0.644 |
|
| 2012 |
Becker R, Dembek C, White LA, Garrison LP. The cost offsets and cost-effectiveness associated with pegylated drugs: a review of the literature. Expert Review of Pharmacoeconomics & Outcomes Research. 12: 775-93. PMID 23252359 DOI: 10.1586/Erp.12.65 |
0.406 |
|
| 2012 |
Wong WB, Ramsey SD, Barlow WE, Garrison LP, Veenstra DL. The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007). Contemporary Clinical Trials. 33: 1117-23. PMID 22981891 DOI: 10.1016/J.Cct.2012.08.006 |
0.36 |
|
| 2012 |
Casciano R, Chulikavit M, Perrin A, Liu Z, Wang X, Garrison LP. Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States. Journal of Medical Economics. 15: 55-64. PMID 22881362 DOI: 10.3111/13696998.2012.720319 |
0.377 |
|
| 2012 |
Thariani R, Veenstra DL, Carlson JJ, Garrison LP, Ramsey S. Paying for personalized care: cancer biomarkers and comparative effectiveness. Molecular Oncology. 6: 260-6. PMID 22429896 DOI: 10.1016/J.Molonc.2012.02.006 |
0.404 |
|
| 2012 |
Babigumira JB, Stergachis A, Veenstra DL, Gardner JS, Ngonzi J, Mukasa-Kivunike P, Garrison LP. Potential cost-effectiveness of universal access to modern contraceptives in Uganda. Plos One. 7: e30735. PMID 22363480 DOI: 10.1371/Journal.Pone.0030735 |
0.682 |
|
| 2012 |
Garrison L, Babigumira J, Andrade S. PCN91 The Cost-Effectiveness of Trastuzumab Over the Product Life Cycle in Portugal: A Dynamic and Societal Perspective Value in Health. 15: A425. DOI: 10.1016/J.Jval.2012.08.2131 |
0.605 |
|
| 2011 |
Garrison LP, Lalla D, Brammer MG, Wang B, Babigumira J, Perez EA. Assessing the potential cost-effectiveness of retesting IHC0, IHC1-positive, or FISH-negative early-stage breast cancer patients for HER2 status. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 6133. PMID 28022481 DOI: 10.1200/jco.2011.29.15_suppl.6133 |
0.597 |
|
| 2011 |
Ramsey SD, Veenstra D, Tunis SR, Garrison L, Crowley JJ, Baker LH. How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment. Health Affairs (Project Hope). 30: 2259-68. PMID 22147853 DOI: 10.1377/Hlthaff.2010.0637 |
0.352 |
|
| 2011 |
Babigumira JB, Stergachis A, Veenstra DL, Gardner JS, Ngonzi J, Mukasa-Kivunike P, Garrison LP. Estimating the costs of induced abortion in Uganda: a model-based analysis. Bmc Public Health. 11: 904. PMID 22145859 DOI: 10.1186/1471-2458-11-904 |
0.691 |
|
| 2011 |
Flum DR, Kwon S, MacLeod K, Wang B, Alfonso-Cristancho R, Garrison LP, Sullivan SD. The use, safety and cost of bariatric surgery before and after Medicare's national coverage decision. Annals of Surgery. 254: 860-5. PMID 21975317 DOI: 10.1097/Sla.0B013E31822F2101 |
0.343 |
|
| 2011 |
Levin A, Burgess C, Garrison LP, Bauch C, Babigumira J, Simons E, Dabbagh A. Global eradication of measles: an epidemiologic and economic evaluation. The Journal of Infectious Diseases. 204: S98-106. PMID 21666220 DOI: 10.1093/Infdis/Jir096 |
0.655 |
|
| 2011 |
Garrison LP, Bauch CT, Bresnahan BW, Hazlet TK, Kadiyala S, Veenstra DL. Using cost-effectiveness analysis to support research and development portfolio prioritization for product innovations in measles vaccination. The Journal of Infectious Diseases. 204: S124-32. PMID 21666153 DOI: 10.1093/Infdis/Jir114 |
0.429 |
|
| 2011 |
Babigumira JB, Levin A, Burgess C, Garrison LP, Bauch CT, Braka F, Mbabazi WB, Nabyonga JO, Simons E, Dabbagh A. Assessing the cost-effectiveness of measles elimination in Uganda: local impact of a global eradication program. The Journal of Infectious Diseases. 204: S116-23. PMID 21666152 DOI: 10.1093/Infdis/Jir132 |
0.684 |
|
| 2011 |
Babigumira JB, Castelnuovo B, Stergachis A, Kiragga A, Shaefer P, Lamorde M, Kambugu A, Muwanga A, Garrison LP. Cost effectiveness of a pharmacy-only refill program in a large urban HIV/AIDS clinic in Uganda. Plos One. 6: e18193. PMID 21464895 DOI: 10.1371/Journal.Pone.0018193 |
0.672 |
|
| 2011 |
Cross JT, Veenstra DL, Gardner JS, Garrison LP. Can modeling of health outcomes facilitate regulatory decision making? The benefit-risk tradeoff for rosiglitazone in 1999 vs. 2007. Clinical Pharmacology and Therapeutics. 89: 429-36. PMID 21289618 DOI: 10.1038/Clpt.2010.350 |
0.335 |
|
| 2011 |
Nichols GA, Arondekar B, Garrison LP. Patient characteristics and medical care costs associated with hypertriglyceridemia. The American Journal of Cardiology. 107: 225-9. PMID 21211599 DOI: 10.1016/J.Amjcard.2010.09.010 |
0.354 |
|
| 2011 |
Roth JA, Garrison LP, Burke W, Ramsey SD, Carlson R, Veenstra DL. Stakeholder perspectives on a risk-benefit framework for genetic testing. Public Health Genomics. 14: 59-67. PMID 20407215 DOI: 10.1159/000290452 |
0.312 |
|
| 2010 |
Postma MJ, Milne G, Nelson EA, Pyenson B, Basili M, Coker R, Oxford J, Garrison LP. Pharmaceutical interventions for mitigating an influenza pandemic: modeling the risks and health-economic impacts. Expert Review of Anti-Infective Therapy. 8: 1431-9. PMID 21133667 DOI: 10.1586/Eri.10.136 |
0.314 |
|
| 2010 |
Garrison LP. Regulatory benefit-risk assessment and comparative effectiveness research: strangers, bedfellows or strange bedfellows? Pharmacoeconomics. 28: 855-65. PMID 20831293 DOI: 10.2165/11538640-000000000-00000 |
0.378 |
|
| 2010 |
Veenstra DL, Roth JA, Garrison LP, Ramsey SD, Burke W. A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 12: 686-93. PMID 20808229 DOI: 10.1097/Gim.0B013E3181Eff533 |
0.337 |
|
| 2010 |
Levy AR, Garrison LP. Apples and Oranges? Assessing Comparative Effectiveness and Comparative Value in the US and Other Countries. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 13: S1-3. PMID 20618787 DOI: 10.1111/J.1524-4733.2010.00754.X |
0.332 |
|
| 2010 |
Best JH, Garrison LP. Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer. Expert Review of Pharmacoeconomics & Outcomes Research. 10: 103-14. PMID 20384557 DOI: 10.1586/Erp.10.12 |
0.367 |
|
| 2010 |
Cheng MM, Alfonso R, Best JH, Garrison LP, Bruhn D, Veenstra DL. The economic value of reducing medication dosing frequency with drug delivery technologies: an evidence assessment. Journal of Medical Economics. 13: 193-202. PMID 20334490 DOI: 10.3111/13696991003757500 |
0.389 |
|
| 2010 |
Towse A, Garrison LP. Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics. 28: 93-102. PMID 20085386 DOI: 10.2165/11314080-000000000-00000 |
0.333 |
|
| 2010 |
Best JH, Garrison LP, Hollingworth W, Ramsey SD, Veenstra DL. Preference values associated with stage III colon cancer and adjuvant chemotherapy. Quality of Life Research : An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. 19: 391-400. PMID 20084462 DOI: 10.1007/S11136-010-9589-5 |
0.344 |
|
| 2010 |
Garrison LP, Mansley EC, Abbott TA, Bresnahan BW, Hay JW, Smeeding J. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 13: 8-13. PMID 19883405 DOI: 10.1111/J.1524-4733.2009.00660.X |
0.407 |
|
| 2010 |
Hay JW, Smeeding J, Carroll NV, Drummond M, Garrison LP, Mansley EC, Mullins CD, Mycka JM, Seal B, Shi L. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 13: 3-7. PMID 19874571 DOI: 10.1111/J.1524-4733.2009.00663.X |
0.437 |
|
| 2010 |
Wang S, Huang H, Shi H, Dun M, Chen K, Chang E, Korves C, Dhawan R, Cakana A, van de Velde H, Esseltine D, Garrison L. PSY29 MODELING THE COST-EFFECTIVENESS OF BORTEZOMIB FOR THE INITIAL TREATMENT OF MULTIPLE MYELOMA IN THE UNITED STATES Value in Health. 13: A210. DOI: 10.1016/S1098-3015(10)73031-X |
0.373 |
|
| 2010 |
Flum DR, Kwon S, MacLeod K, Wang B, Alfonso R, Garrison LP, Sullivan SD. The impact of accreditation-based coverage decisions on the safety and cost of bariatric surgery Journal of the American College of Surgeons. 211: S96-S97. DOI: 10.1016/J.Jamcollsurg.2010.06.254 |
0.343 |
|
| 2009 |
Babigumira JB, Castelnuovo B, Lamorde M, Kambugu A, Stergachis A, Easterbrook P, Garrison LP. Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda. Bmc Health Services Research. 9: 192. PMID 19845963 DOI: 10.1186/1472-6963-9-192 |
0.666 |
|
| 2009 |
Carlson JJ, Garrison LP, Sullivan SD. Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals. Journal of Managed Care Pharmacy : Jmcp. 15: 683-7. PMID 19803557 DOI: 10.18553/Jmcp.2009.15.8.683 |
0.412 |
|
| 2009 |
Garrison LP, Veenstra DL. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 12: 1118-23. PMID 19624617 DOI: 10.1111/J.1524-4733.2009.00572.X |
0.407 |
|
| 2009 |
Garrison LP. Editorial: On the benefits of modeling using QALYs for societal resource allocation: the model is the message. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 12: S36-7. PMID 19250130 DOI: 10.1111/J.1524-4733.2009.00520.X |
0.391 |
|
| 2009 |
Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 12: 20-7. PMID 18647257 DOI: 10.1111/J.1524-4733.2008.00415.X |
0.41 |
|
| 2009 |
Wang S, Huang H, Shi H, Duh MS, Chen K, Chang E, Korves C, Dhawan R, Cakana A, van de Velde H, Esseltine D, Garrison L. The Cost-Effectiveness of Bortezomib for the Initial Treatment of Multiple Myeloma in the United States. Blood. 114: 1379-1379. DOI: 10.1182/Blood.V114.22.1379.1379 |
0.481 |
|
| 2009 |
Garrison L, Bauch C, Babigumira J. VA3 GLOBAL MEASLES ERADICATION: COST-EFFECTIVENESS AND IMPLICATIONS FOR GHANA, 2020–2049 Value in Health. 12: A228. DOI: 10.1016/S1098-3015(10)74114-0 |
0.641 |
|
| 2009 |
Bresnahan B, Babigumira J, Veenstra D, Bauch C, Garrison L. PIN39 ASSESSING DISEASE BURDEN FOR MEASLES USING A CLINICAL AND HEALTH OUTCOMES APPROACH: A FOCUS ON LOWER-INCOME COUNTRIES Value in Health. 12: A117. DOI: 10.1016/S1098-3015(10)73647-0 |
0.576 |
|
| 2008 |
Babigumira J, Castelnuovo B, Lamorde M, Muwanga A, Kambugu A, Easterbrook P, Garrison L. PIN9 THE WORKFORCE AND COST IMPLICATIONS OF SUBSTITUTING NURSES AND PHARMACISTS FOR DOCTORS IN THE FOLLOW-UP OF PATIENTS WITH AIDS ON ANTIRETROVIRALTHERAPY IN UGANDA Value in Health. 11: A94-A95. DOI: 10.1016/S1098-3015(10)70307-7 |
0.621 |
|
| 2008 |
Sullivan S, Garrison L, Rinde H, Kolberg J, Moler E, Urdea M. OM4 LONG-TERM COST-EFFECTIVENESS OF A DIABETES RISK SCORE IN CLINICAL PRACTICE Value in Health. 11: A21. DOI: 10.1016/S1098-3015(10)70079-6 |
0.327 |
|
| 2007 |
Garrison LP, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer. 110: 489-98. PMID 17592827 DOI: 10.1002/Cncr.22806 |
0.365 |
|
| 2007 |
Garrison LP, Towse A, Bresnahan BW. Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. Health Affairs (Project Hope). 26: 684-95. PMID 17485745 DOI: 10.1377/Hlthaff.26.3.684 |
0.326 |
|
| 2007 |
Garrison LP, Austin MJF. The economics of personalized medicine: A model of incentives for value creation and capture Drug Information Journal. 41: 501-509. DOI: 10.1177/009286150704100408 |
0.36 |
|
| 2007 |
Meckley L, Austin M, Garrison L, Veenstra D. PCV56 THE COST-EFFECTIVENESS LANDSCAPE OF GENETIC TESTING WITH WARFARIN THERAPY Value in Health. 10: A53. DOI: 10.1016/S1098-3015(10)68698-6 |
0.353 |
|
| 2007 |
Sander B, Nizam A, Garrison L, Postma M, Halloran M, Longini Jr I. IN4 ECONOMIC EVALUATION OF INFLUENZA PANDEMIC MITIGATION STRATEGIES IN THE US USING A STOCHASTIC MICROSIMULATION INFLUENZA MODEL Value in Health. 10: A19. DOI: 10.1016/S1098-3015(10)68589-0 |
0.37 |
|
| 2006 |
Cassidy J, Douillard JY, Twelves C, McKendrick JJ, Scheithauer W, Bustová I, Johnston PG, Lesniewski-Kmak K, Jelic S, Fountzilas G, Coxon F, Díaz-Rubio E, Maughan TS, Malzyner A, Bertetto O, ... ... Garrison LP, et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. British Journal of Cancer. 94: 1122-9. PMID 16622438 DOI: 10.1038/sj.bjc.6603059 |
0.368 |
|
| 2006 |
Morden NE, Garrison LP. Implications of Part D for mentally ill dual eligibles: a challenge for Medicare. Health Affairs (Project Hope). 25: 491-500. PMID 16522603 DOI: 10.1377/Hlthaff.25.2.491 |
0.316 |
|
| 1997 |
Hornberger JC, Best JH, Garrison LP. Cost-effectiveness of repeat medical procedures: Kidney transplantation as an example Medical Decision Making. 17: 363-372. PMID 9343794 DOI: 10.1177/0272989X9701700401 |
0.385 |
|
| 1992 |
Garrison LP. Assessment of the effectiveness of supply-side cost-containment measures. Health Care Financing Review. 1991: 13-20. PMID 25372721 |
0.352 |
|
| 1986 |
Garrison LP, Wilensky GR. Cost containment and incentives for technology Health Affairs (Project Hope). 5: 46-58. PMID 3527916 DOI: 10.1377/Hlthaff.5.2.46 |
0.368 |
|
| 1984 |
Garrison LP, Bowman MA, Perrin EB. Estimating physician requirements for neurology: A needs-based approach Neurology. 34: 1218-1227. PMID 6540408 DOI: 10.1212/Wnl.34.9.1218 |
0.304 |
|
| Show low-probability matches. |